Treatment outcomes for isoniazid-resistant tuberculosis under program conditions in British Columbia, Canada

BMC Infectious Diseases

Table 5 Comparison of characteristics with favourable versus unfavourable outcomes

Characteristic (n, %)	Successful outcome^a (n = 140)	Unsuccessful outcome^b (n = 12)	P value
Patient characteristics
Co-morbidity (HIV, DM, Malignancy, CKD, immune suppressive medication)	36 (25.7)	3 (25.0)	1.00
Smear positive disease^c	64 (60.4)	5 (50.0)	0.523
Cavitary disease^c	41 (38.7)	5 (50.0)	0.515
Prior TB treatment^d	19 (14.4)	2 (22.2)	0.623
Resistance profile
High level INH resistance	69 (49.3)	7 (58.3)	0.547
Treatment regimen
> 2 months pyrazinamide	66 (47.1)	7 (58.3)	0.456
> 9 months rifampin	69 (49.3)	3 (25.0)	0.106
≥ 4 effective drugs in intensive phase	25 (17.9)	3 (25.0)	0.464
Fluoroquinolone containing regimen	52 (37.1)	4 (33.3)	0.793

^aA successful outcome included patients meeting the definition of Cure or Treatment Completed without Relapse
^bAn unsuccessful outcome included patients meeting the definition of Treatment Failure, Acquire Drug Resistance, Death, or Relapse
^cThe denominator used to calculate percentage for smear positive disease was based on those with pulmonary involvement and primary study outcome (successful outcome n = 106; unsuccessful outcome n = 10)
^dMissing data for 8 successful outcomes and 1 unsuccessful outcome

ISSN: 1471-2334